Market research
FHTX Foghorn Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 420M
- P/E ratio
- Not available
- Analyst target
- 11.4444
- Dividend yield
- Not available
- Beta
- 2.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US3441741077
- Market cap
- 420M
- P/E ratio
- Not available
- Analyst target
- 11.4444
- Dividend yield
- Not available
- Beta
- 2.83
About
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FHTX discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 74.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 340.7.
Based on the above factors, Foghorn Therapeutics Inc gets an overall score of 1/5.